WASHINGTON — Vienna, Virginia-based biotechnology company Cel-Sci, currently running late-stage clinical trials with patients for its head and neck cancer treatment, watched its stock fall more than 30 percent in early Tuesday trading …
On November 17, 2017, Tekla Life Sciences Investors declared a stock distribution of $0.43 per share. The record date for the stock distribution is November 28, 2017 and the payable date is December 29, 2017. The Fund will trade ex …
The surprising part is that Gilead's shares slumped last month despite the late-stage success of its next major HIV single-tablet drug regimen: a fixed-dose combination of bictegravir and emtricitabine/tenofovir alafenamide indicated for the …
* Cel-Sci Corp - a 1-for-25 reverse split was authorized for its outstanding shares of common stock Source text for Eikon: Further company coverage: Our Standards:The Thomson Reuters Trust Principles.
In May, Andrew Left of Citron Research blasted Exact Sciences (NASDAQ: EXAS), calling the stock "a poster child for what goes wrong when Wall Street gets a hold of a healthcare concept with no discrimination for whether it's good or …
Yahoo!1mon
The past year has been rough onExact Sciences' stock. After successfully navigating key product Cologuard through the regulatory and reimbursement maze, sales expectations were sky-high -- and so was the stock. At its peak, the …